FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Company

FDC LTD

Pharmaceutical intelligence for FDC LTD with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Assets: 2

Recent signals(2)

StrategyJuly 16, 2026

FDA Grants Approval for Cefixime ANDA218691 by FDC LTD

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 218691 for Cefixime submitted by FDC LTD.

StrategyJune 21, 2026

FDA Grants AP Status for Dorzolamide Hydrochloride ANDA205294

The FDA has granted Abbreviated Approval (AP) status for ANDA205294, a generic formulation of Dorzolamide Hydrochloride.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

Cefixime →

FDA →

Therapeutic areas

Indications

Infectious Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.